Neurotech’s NTI164 Shows Promise in Autism Trial

Neurotech International Ltd. (AU:NTI) has released an update.

Neurotech International Ltd reports promising results from its Phase II/III clinical trial for Autism Spectrum Disorder (ASD), showing significant improvements in ASD symptoms for patients treated with NTI164. After 12 weeks of treatment, patients displayed a 56% improvement from the trial’s baseline, with symptoms becoming barely noticeable. The trial also noted that patients switching from placebo to NTI164 experienced a 21% improvement in just four weeks.

For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.